Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 13,314 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the transaction, the senior vice president owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Stock Up 0.1%

TBPH opened at $16.71 on Thursday. The business’s fifty day simple moving average is $16.49 and its 200 day simple moving average is $17.40. Theravance Biopharma, Inc. has a 52 week low of $10.44 and a 52 week high of $21.03. The stock has a market cap of $861.40 million, a PE ratio of 7.60 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, equities analysts anticipate that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on TBPH. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. BTIG Research restated a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. TD Cowen lifted their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. Finally, HC Wainwright boosted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $21.40.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently bought and sold shares of TBPH. Mirae Asset Global Investments Co. Ltd. lifted its position in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the period. Creative Planning raised its holdings in Theravance Biopharma by 6.7% during the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 842 shares during the last quarter. State of Wyoming raised its holdings in Theravance Biopharma by 5.7% during the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 1,019 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Theravance Biopharma by 6.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 1,020 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.